Establishing a druggable target for KRAS driven cancers

For almost 30 years, the protein KRAS has been the "undruggable target" of cancer research.  Gene mutations in KRAS are responsible for 33% of all human cancers, including pancreatic, lung, and colon cancer.

A new molecule identified by Dr. Bhairavi Tolani, an assistant professor at the University of California, San Francisco  upends conventional concepts of directly targeting the protein KRAS as a treatment strategy. Instead she suggests an alternative avenue for treatment of these deadliest cancers.

Read her original research in Nature Biotechnology here: https://doi.org/10.1038/s41587-022-01386-z